You are on page 1of 1

C 92/2 EN Official Journal of the European Communities 27.3.

98

Summary of Community decisions on marketing authorisations in respect of medicinal products


from 15 February 1998 to 15 March 1998
(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93Ø(Î))

(98/C 92/02)

— Issuing of a marketing authorisation (Article 12 of Council Regulation (EEC) No 2309/93)

Date of the Name of the Number of the entry in the Date of


Holder of the marketing authorisation
Decision medicinal product Community Register notification

23.2.1998 Mirapexin PharmaciaØ@ØUpjohn SA EU/1/97/051/001-010 24.2.1998


52, route d’Esch
L-1470 Luxembourg

— Modification of a marketing authorisation (Article 12 of Council Regulation (EEC) No


2309/93)

Date of the Name of the Number of the entry in the Date of


Decision medicinal product Holder of the marketing authorisation Community Register notification

3.3.1998 Cystagon Orphan Europe SARL EU/1/97/039/001-004 4.3.1998


Immeuble ‘Le Guillaumet’
60, avenue du Pr~sident Wilson
F-92046 Paris-la-D~fense

3.3.1998 Humalogpen Eli Lilly Nederland BV EU/1/97/042/001 4.3.1998


Krijtwal 17-23
NL-3432 ZT Nieuwegein

3.3.1998 Zyprexa Eli Lilly Nederland BV EU/1/96/022/001-010 4.3.1998


Krijtwal 17-23
NL-3432 ZT Nieuwegein

3.3.1998 Olansek Eli Lilly and Company Limited EU/1/96/021/001-010 4.3.1998


Kingsclere Road
Basingstoke, Hampshire
United Kingdom
10.3.1998 Humalog Eli Lilly Nederland BV EU/1/96/007/003-004 11.3.1998
Krijtwal 17-23
NL-3432 ZT Nieuwegein
11.3.1998 Fareston Orion Corporation EU/1/96/004/001-002 13.3.1998
Orionintie 1
FIN-02200 Espoo

Anyone wishing to consult the public assessment report on the medicinal products in question
and the decisions relating thereto is invited to contact:

The European Agency for the Evaluation of Medicinal Products


7, Westferry Circus, Canary Wharf
London E14 4HB
United Kingdom

(Î)ÙOJ L 214, 24.8.1993, p. 1.